翰宇藥業(300199.SZ):實控人曾少貴向賴漢宣轉讓5%股份事項終止
格隆匯7月12日丨翰宇藥業(300199.SZ)公佈,此前披露,實際控制人曾少貴擬向賴漢宣協議轉讓其持有的45,846,352股股份,約佔公司總股本的5.00%(佔剔除公司回購專户股份後總股本的5.19%)。
公司於今日接到控股股東曾少貴的通知,曾少貴與賴漢宣進行協商並達成一致,決定對雙方於2021年7月1日簽署的《曾少貴與賴漢宣關於深圳翰宇藥業股份有限公司之股份轉讓協議》予以解除,並簽訂《合同終止協議》。
截至公吿披露日,上述股份轉讓協議擬轉讓的股份未在中國證券登記結算有限責任公司深圳分公司辦理過户登記手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.